Yeah, I was wondering about the need for phase 3 t
Post# of 148292
Another thought I had was if the drug/placebo ratio could be increased in the 2b/3 to help improve enrollment incentive (e.g. 3:1, 4:1 - not sure how many need to be in the placebo control arm in order to remain statistically significant)
Ultimately I'm just thinking out loud here and I don't expect any changes to be made, at least not in the near term. The company line seems to have been that they "expect enrollment to accelerate soon" for the entirety of April.